Loading
Oleclumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer, triple-negative breast cancer and colorectal cancer, with its target not yet stated publicly.
Oleclumab (MEDI9447) is an investigational agent whose form is not stated in the registry developed by AstraZeneca and MedImmune. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description. It is the investigational product in 7 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer), in non-small-cell lung cancer, triple-negative breast cancer and colorectal cancer. The largest, NCT05221840, plans to enrol 1051 participants (actual) with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Oleclumab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Oleclumab" OR ABSTRACT:"Oleclumab" OR TITLE:"MEDI9447" OR ABSTRACT:"MEDI9447") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Oleclumab, not a curated reading list.
Shares A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer, The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2, Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer, AstraZeneca and the tag pipeline.
Shares Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy, AstraZeneca, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.